Newsfeeds - Spark Newswire

1 minute read

Gilead Trims Non-COVID Product Sales Outlook, Though Q3 Earnings Beat Street Estimates

Today, 8:28 AM

Gilead Sciences Inc (NASDAQ:GILD) posted higher-than-expected Q3 earnings on strong demand for its COVID-19 antiviral treatment. Adjusted EPS increased 26% Y/Y…

GILD

1 minute read

Gilead Sciences Q3 EPS $2.65 Beats $1.74 Estimate, Sales $7.40B Beat $6.25B Estimate

By Benzinga Newsdesk

Today, 8:28 AM

Gilead Sciences (NASDAQ:GILD) reported quarterly earnings of $2.65 per share which beat the analyst consensus estimate of $1.74 by 52.3 percent. This is a 25.59 percent increase over earnings of $2.11 per share from the

GILD

19 minute read

Earnings Scheduled For October 28, 2021

By Benzinga Insights

Today, 8:28 AM

Companies Reporting Before The Bell • LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million.

AAPL

4 minute read

The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech’s Vaccine For Children

By Shanthi Rexaline

Today, 8:28 AM

Here's a roundup of top developments in the biotech space over the last 24 hours:

ANAB

2 minute read

FDA
News

Gilead Sciences Says Sacituzumab Govitecan Receives Positive CHMP Opinion As 2L Treatment For Adult Patients With Metastatic Triple-Negative Breast Cancer

By Benzinga Newsdesk

Today, 8:28 AM

Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for sacituzumab govitecan as

GILD

3 minute read

This Company Revolutionizes What Matters for Hospitals, Big Pharma and Health Insurers

By Kathy Hauer

Today, 8:28 AM

You can perch on a 1-legged stool and balance precariously on 2, but if you want to settle in with comfort and safety, you need 3 sturdy legs.

ABBV

1 minute read

Morgan Stanley Maintains Overweight on Gilead Sciences, Raises Price Target to $84

By Benzinga Newsdesk

Today, 8:28 AM

Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $83 to $84.

GILD

4 minute read

Molnupiravir? Not So Fast. What About Tollovir? — Here’s Why You Should Know What That Means

By Ernest Dela Aglanu

Today, 8:28 AM

Photo by Martin Sanchez on

AVIR

3 minute read

NanoViricides Leaps Forward in its Quest to Defeat COVID-19

By Kim Griffin

Today, 8:28 AM

Photo by Louis Reed on Unsplash

GILD

5 minute read

Tesla and Merck Give Investors Some Hope

By JJ Kinahan

Today, 8:28 AM

Friday’s rally appears to have lost its momentum over the weekend because stock futures are trading lower before Monday’s open. China’s troubled real estate developer Evergrande continues to be a drag on stocks. Hong Kong’s Hang Seng Index (HIS:HK) dropped 2% as trading on Evergrande was halted.

GILD